Back

Watch Compare

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Data quality: 83%

RVPH

NASDAQ Manufacturing Chemicals

$0.89

▲ $0.03 (3.35%)

6 months return

—

Momentum

Neutral

ROE

-971.25%

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-971.25%

Below sector avg (-54.47%)

ROIC-748.32%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

0.00

Below sector avg (0.30)

Current Ratio1.39

Interest Coverage-1507.24

Valuation

PE (TTM|NTM)

-0.55 | -0.93

Above sector avg (-1.50)

P/B Ratio2.40

EV/EBITDAN/A

Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Debt/Equity of 0.00 — conservative balance sheet

Negative free cash flow of -24.59 M

Price History

Financial Trends

Analyst Price Target

5 analysts

Buy

+6474.8%

upside to target

Current

$0.89

Consensus Target

$58.20

$1.00

Low

$140.00

High

Forecast

Forward P/E

-0.93

Forward EPS

-$0.83

Est. Revenue

0.0

Earnings Surprises

EPS

Reported Estimate Forecast

Next: Q1 2026 · EPS Est: -$0.93 · Rev Est: 0.0

	Q12025	Q22025	Q32025	Q42025	Q1 '26	Q2 '26
Reported	-$2.60	-$2.40	-$1.20	-$5.19	—	—
Estimate	-$3.65	-$2.20	-$1.94	-$1.07	-$0.93	-$0.96
Surprise	+28.77%	-9.09%	+38.24%	-386.56%	—	—

Growth

Rev 5Y: N/A · Earnings 1Y: N/A

Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A

Profitability

ROE: -971.25% · Net Margin: N/A

Revenue (TTM)	N/A	Net Income (TTM)	-19.86 M
ROE	-971.25%	ROA	-153.00%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-24.59 M
ROIC	-748.32%	FCF Growth (3Y)	N/A

Safety

D/E: 0.00 · Current: 1.39

Debt / Equity	0.00	Current Ratio	1.39
Interest Coverage	-1507.24	Asset Turnover	N/A
Working Capital	3.77 M	Tangible Book Value	4.55 M

Dividends

Yield: N/A · Payout: N/A

Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A

Valuation

P/E: -0.55 · EV/EBITDA: N/A

P/E Ratio	-0.55	Forward P/E	-0.93
P/B Ratio	2.40	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-225.18%
Market Cap	10.92 M	Enterprise Value	-2.26 M

Per Share

EPS: N/A · FCF/Share: -1.92

EPS (Diluted TTM)	N/A	Revenue / Share	N/A
FCF / Share	-1.92	OCF / Share	-1.92
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A

Efficiency

FCF Conv: 123.81% · CapEx/Rev: N/A

CapEx / Revenue	N/A	FCF Conversion	123.81%
SBC-Adj. FCF	-26.72 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	—	—	—	—
Net Income	-19.86 M	-29.92 M	-39.26 M	-24.34 M	-8.52 M
EPS (Diluted)	—	—	—	—	—
Gross Profit	—	—	—	—	—
Operating Income	-20.20 M	-30.80 M	-39.50 M	-24.31 M	-10.10 M
EBITDA	—	—	—	—	—
R&D Expenses	11.71 M	22.91 M	31.42 M	18.95 M	4.85 M
SG&A Expenses	—	—	—	—	—
D&A	—	—	—	—	—
Interest Expense	13,402.0	18,497.0	—	—	0.0
Income Tax	18,889.0	19,514.0	16,949.0	20,777.0	8,281.0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	15.92 M	15.50 M	23.70 M	18.92 M	31.40 M
Total Liabilities	7.28 M	14.69 M	17.98 M	6.61 M	2.72 M
Shareholders' Equity	8.65 M	812,572.0	5.72 M	12.32 M	28.69 M
Total Debt	406,875.0	458,154.0	—	—	—
Cash & Equivalents	14.44 M	13.48 M	23.37 M	18.52 M	29.69 M
Current Assets	15.10 M	14.68 M	—	—	—
Current Liabilities	7.28 M	14.60 M	17.18 M	6.04 M	2.34 M

Peer Comparison

vs Manufacturing sector median (1605 peers)

Metric	Stock	Sector Median
P/E	-0.6	-1.5
P/B	2.4	1.6
ROE %	-971.3	-54.5
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.7
D/E	0.0	0.3